At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,025 enrolled
Drug / intervention
Meningococcal vaccine GSK134612 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax™ ACWY
In Brief
A Phase 3 clinical trial evaluating Meningococcal vaccine GSK134612 and Mencevax™ ACWY for Infections, Meningococcal. Completed, enrolled 1,025 participants across 7 sites in 3 countries.
Detailed Summary
The purpose of this study is to demonstrate, in 11-17 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesIndia, Philippines, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartMay 2007
Primary CompletionApr 2008
Study CompletionSep 2008
TodayJul 2026
First PostedApr 24, 2007
Enrollment StartMay 2, 2007
Primary CompletionApr 16, 2008
Study CompletionSep 10, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.2 years ago
Interventions
Meningococcal vaccine GSK134612biological
One intramuscular dose
Mencevax™ ACWYbiological
One subcutaneous dose